Abstract
As a new technology in the management of valvular heart disease, transcatheter aortic valve replacement (TAVR) has drawn much attention since its emergence. To date, numerous studies have investigated the safety and efficacy of TAVR in patients of various risk profiles with severe aortic stenosis (AS) and demonstrated comparable or superior outcomes of TAVR when compared with surgical aortic valve replacement (SAVR). The favorable outcomes of TAVR in inoperable patients, as well as in high- and intermediaterisk patients, are endorsed in current guidelines, and trials of low-risk patients have shown non-inferior or even superior results of TAVR than for SAVR, suggesting that the clinical indications of TAVR can be expanded to low-risk patients. Moreover, a therapeutic role of TAVR has been suggested in various aortic valve (AV) diseases, such as bicuspid AV, moderate AS with heart failure, aortic regurgitation, and bioprosthetic valve failure. In this review, we summarize the current issues of TAVR in various patient populations and discuss the expanding clinical indications of TAVR, which are driving a major paradigm shift in the management of AV disease.
| Original language | English |
|---|---|
| Pages (from-to) | 952-962 |
| Number of pages | 11 |
| Journal | Circulation Journal |
| Volume | 83 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
Keywords
- Aortic stenosis
- Surgical aortic valve replacement
- Transcatheter aortic valve implantation
- Transcatheter aortic valve replacement
- Valve-in-valve
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Current key issues in transcatheter aortic valve replacement undergoing a paradigm shift. / Hwang, In Chang; Hayashida, Kentaro; Kim, Hyo Soo.
In: Circulation Journal, Vol. 83, No. 5, 01.01.2019, p. 952-962.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Current key issues in transcatheter aortic valve replacement undergoing a paradigm shift
AU - Hwang, In Chang
AU - Hayashida, Kentaro
AU - Kim, Hyo Soo
PY - 2019/1/1
Y1 - 2019/1/1
N2 - As a new technology in the management of valvular heart disease, transcatheter aortic valve replacement (TAVR) has drawn much attention since its emergence. To date, numerous studies have investigated the safety and efficacy of TAVR in patients of various risk profiles with severe aortic stenosis (AS) and demonstrated comparable or superior outcomes of TAVR when compared with surgical aortic valve replacement (SAVR). The favorable outcomes of TAVR in inoperable patients, as well as in high- and intermediaterisk patients, are endorsed in current guidelines, and trials of low-risk patients have shown non-inferior or even superior results of TAVR than for SAVR, suggesting that the clinical indications of TAVR can be expanded to low-risk patients. Moreover, a therapeutic role of TAVR has been suggested in various aortic valve (AV) diseases, such as bicuspid AV, moderate AS with heart failure, aortic regurgitation, and bioprosthetic valve failure. In this review, we summarize the current issues of TAVR in various patient populations and discuss the expanding clinical indications of TAVR, which are driving a major paradigm shift in the management of AV disease.
AB - As a new technology in the management of valvular heart disease, transcatheter aortic valve replacement (TAVR) has drawn much attention since its emergence. To date, numerous studies have investigated the safety and efficacy of TAVR in patients of various risk profiles with severe aortic stenosis (AS) and demonstrated comparable or superior outcomes of TAVR when compared with surgical aortic valve replacement (SAVR). The favorable outcomes of TAVR in inoperable patients, as well as in high- and intermediaterisk patients, are endorsed in current guidelines, and trials of low-risk patients have shown non-inferior or even superior results of TAVR than for SAVR, suggesting that the clinical indications of TAVR can be expanded to low-risk patients. Moreover, a therapeutic role of TAVR has been suggested in various aortic valve (AV) diseases, such as bicuspid AV, moderate AS with heart failure, aortic regurgitation, and bioprosthetic valve failure. In this review, we summarize the current issues of TAVR in various patient populations and discuss the expanding clinical indications of TAVR, which are driving a major paradigm shift in the management of AV disease.
KW - Aortic stenosis
KW - Surgical aortic valve replacement
KW - Transcatheter aortic valve implantation
KW - Transcatheter aortic valve replacement
KW - Valve-in-valve
UR - http://www.scopus.com/inward/record.url?scp=85065219426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065219426&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-19-0096
DO - 10.1253/circj.CJ-19-0096
M3 - Article
C2 - 30956265
AN - SCOPUS:85065219426
VL - 83
SP - 952
EP - 962
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 5
ER -